Drug intelligence / Profile preview

BH-501352

Development stage: Unknown
Lead developer: Bio-Thera Solutions
Modality: Small Molecules
Administration: Oral

Overview

BH-501352 is one of three molecules in BlossomHill Therapeutics' pan-KRAS inhibitor programme, presented at AACR 2026 alongside the lead BH-501284 and BH-501242. Corrected from a record that described it as a Bio-Thera Solutions FGFR inhibitor; see pipeline issue #959.

Targets

FGFR2 (Keratinocyte growth factor receptor)FGFR1 (Fibroblast growth factor receptor 1)FGFR3 (Fibroblast growth factor receptor 3)

Beyond the preview

Go deeper on BH-501352.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BH-501352.

Explore the full profile